EGFR and neoplasm: Moreover, Arena et al. showed that MM-151 decreased and stabilized EGFR ECD mutations in circulating cell-free tumor DNA (ctDNA) of mCRC patients who developed EGFR ECD mutations as a result of treatment with cetuximab or panitumumab (Arena et al., 2016).